Nasdaq-listed biotech company Oculis announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares at a price of $20.00 per share, for total gross proceeds of $100 million. Proceeds will be used to advance and accelerate its clinical development pipeline, particularly the development of its novel neuroprotective clinical candidate Privosegtor (OCS-05).
This Offering follows the release of recent groundbreaking data from the Phase 2 ACUITY trial of OCS-05 (Privosegtor), which has the potential to be the first neuroprotective treatment in ophthalmology, in patients with acute optic neuritis. Data showed OCS-05 met the primary endpoint of safety, in addition to key secondary endpoints that highlighted its neuroprotective structural benefits and the ability to improve visual function in this disease area, with potential to expand across multiple ophthalmic and neurological conditions, including glaucoma.
Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline of multiple innovative product candidates in development includes: OCS-01, a topical eye drop candidate for diabetic macular edema; Privosegtor (OCS-05) and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease.
Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
Please login or sign up to comment.
Commenting guidelines